Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B Warren, Lawrence Green, Kristian Reich, Richard G Langley, Carle Paul, Akihiko Asahina, Lynne Johnson, Vipin Arora, Olawale Osuntokun, Mark Lebwohl
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study'. Together they form a unique fingerprint.